News for Anika Therapeutics, Inc. (ANIK)

Anika Therapeutics' (NASDAQ:ANIK) stock falls as the company's cartilage repair product Hyalofast misses key trial endpoints in a U.S.-based study. Read more here.

Anika Therapeutics, Inc. (NASDAQ:ANIK) Q2 2025 Earnings Conference Call July 30, 2025 8:30 AM ETCompany ParticipantsCheryl Renee Blanchard - President, CEO...

U.S. stock futures showed modest gains on Wednesday morning, July 30, 2025, as Wall Street collectively held its breath in anticipation of a pivotal Federal

Regenerative Solutions revenue up 41% with Integrity™ Implant System ahead of expectations and continued strong Hyalofast® growth; Integrity surpasses full year 2024 performance and is on pace to more than double in 2025

BEDFORD, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its second quarter 2025 financial results before the opening of the market on Wednesday, July 30, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.

Anika Therapeutics (ANIK) grants 2,500 non-statutory stock options to a new non-executive employee. The stock options are priced at $10.53 per share and

Shares of Anika Therapeutics Inc (ANIK) fell 3.06% in mid-day trading on Jun 20. The stock reached an intraday low of $10.67, before recovering slightly to $1

**media[647240]**

BEDFORD, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. ( ANIK), a global leader in the osteoarthritis (”œOA”) pain management and regene

Anika Therapeutics (ANIK) granted stock options to two new non-executive employees. The options cover 5,000 shares at an exercise price of $14.46 each.

On May 12, 2025, Anika Therapeutics (ANIK) received an update from Barrington Research regarding its stock evaluation. Michael Petusky, an analyst at Barrington

Investment firm Barrington has adjusted its price target for Anika Therapeutics (ANIK), reducing it from $20 to $19, while maintaining an Outperform rating. Des

Release Date: May 09, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Anika Therapeutic

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NANIK.OQ - Anika Therapeutics IncQ1 2025 Anika Therapeutics Inc Earnings CallMay 09, 2025 / 12:

Summary: Anika Therapeutics faced a challenging Q1 2025 with a 10% revenue decline, influenced by OEM channel difficulties. Despite pricing pressures fro

Discover Anika Therapeutics' Q1 2025 highlights: strategic pipeline advancements, 18% growth in commercial revenue, and plans for Hyalofast & Cingal's...

The following slide deck was published by Anika Therapeutics, Inc.

Anika Therapeutics, Inc. (NASDAQ:ANIK) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ETCompany ParticipantsMatt Hall - Director, Corporate...

Redburn Atlantic has upgraded MongoDB (MDB) from a Sell to a Neutral rating, with the price target adjusted to $170 from a previous $180. The decision follows t